🔊 @genentech.bsky.social CEO Ashley Magargee shares their 2030 plans, including a groundbreaking molecule for #Alzheimers on stage at #REPharmaUSA with
@reuters.com
🎥 Watch the full interview here 👉https://bit.ly/41gwr2a
#ReutersNEXT #Newsmaker #Pharma #Healthcare
⏰ Don't miss Ashley Magargee’s #Newsmaker interview later today with Reuters Global Pharma Editor Michele Gershberg live from the #REpharmaUSA event in Philadelphia!
👉 Register now to watch live: events.reutersevents.com/reuters/news...
📢 Reuters NEXT Newsmaker:
Join us NEXT Monday to hear Genentech's CEO Ashley Magargee's insights on sweeping shifts underway in U.S. and global health policy.
📆 3/16: 10:10am EST | 2:10pm GMT
👉 Register to watch: events.reutersevents.com/reuters/news...
#Newsmaker #REpharmaUSA #Reuters
Everyone says “patient-first.”
But how do you actually build for it - across silos, systems, and strategy?
Leaders from Pfizer, Amgen, Sanofi, and J&J share how.
⬇️See the full speaker lineup in the brochure: https://ow.ly/9a7l50XgsLu
#REpharmaUSA #PatientCentricity #PharmaInnovation
We’re seeing AI drive smarter segmentation, better engagement, and measurable ROI.
Which innovation has actually moved the needle for your team?
Curious to hear your take. 👇
#PharmaMarketing #AIinPharma #DigitalEngagement #OmnichannelStrategy #PharmaInnovation #REpharma #REpharmaUSA
Seth Ginsberg of the Global Healthy Living Foundation giving a great talk on fighting misinformation:
"We cannot let some TikTok influencer with a ring light and an opinion control the patient narrative." #REpharmaUSA
Today -- where I have been parked in a session largely about health equity -- has been much better about speakers speaking out about the current political situation. I appreciate the speakers who are bravely speaking the truth. #REpharmaUSA
Really striking graphic shared by Gilead's Kesha O'Reilly showing how much access different parts of the country have to clinical trials. The darker blocks have better access and lighter areas have worse access. #REpharmaUSA
"We want as many patients as possible to have access to our drugs. ... But the thing is, that's the scariest thing in the world for a payer," Restivo says. "Who is the right patient? That's what we want to communicate. And has the data really set us up for that?" #REpharmaUSA
A good insight from Bayer's Jennifer Rustivo about PBMs. While HEOR researchers focus on total cost of care, PBMs, who control 80% of covered lives in the US, are really only interested in pharmacy costs. #REpharmaUSA
Sometimes that's a particular disease state and sometimes it's a specific population demographic. But payers and health systems don't want general data, they want specific data about their population, Unni says. #REpharmaUSA
"It is kind of difficult for people who have worked in pharma their entire career to understand what really happens in a payer environment or a health system," Sanjay Unni says. "...People in our industry lack understanding about how payers are uniquely interested in their populations." #REpharmaUSA
Boehringer Ingelheim's Paul Petraro and Sanjay Unni are discussing the concept of "holistic real-world evidence". The be-all and end-all of data collection is no longer the clinical trial, Petraro says. The data lifecycle is much longer and has to be considered in full from the start. #REpharmaUSA
Despite Trump's DEI purge, CMS's Health Equity Index in star ratings and Enhancing Oncology Model are still online. #REpharmaUSA
"There's a growing recognition of health equity concerns and the importance of social drivers of health," Grossman says. "And I don't think this is going away. I think there is still importance in looking at this." #REpharmaUSA
Today I'm in the "Value-Driven" session and it's starting off with a great talk by Bayer's Jamie Grossman about health equity in oncology -- a topic that's never been more important. #REpharmaUSA
Last panel of the day is a panel sponsored by pharmaphorum's parent company EVERSANA. It's focused on direct-to-patient access models, a topic I'm genuinely very excited for. #REpharmaUSA
Chema Avila from Sanofi is up now in the AI track at #REpharmaUSA. He says that Netflix has primed us all to expect a seamless experience from an algorithm that just gets us. Omnichannel marketing is not cutting it when patients and HCPs have that expectation.
Brand name confusion in pharma is a safety issue -- 33% of medication errors are caused by drug name confusion. That's why FDA and EMA get involved and have to approve names. In a completely separate process from the trademark process. #REpharmaUSA
Two years covering pharma and this is the first time I've attended a session about drug naming. Who knew there was so much to it!? #REpharmaUSA
My question is “waiting for review”. Several others have been approved since I sent it. Disappointing. #REpharmaUSA
Interesting insight from PhRMA's Michael Ybarra about PBM reform. I have often wondered "if there's such a broad consensus PBM reform is needed, why hasn't it happened?". Ybarra says different stakeholders have different grievances with PBMs, so reform efforts aren't always unified. #REpharmaUSA
This is kind of a surreal experience at #REpharmaUSA. This panel is all about preventative medicine & panelists are talking about vaccination and food as medicine, but no one is talking about the fact that there's a famous vaccine denier heading up HHS and the Trump administration just killed USAID.
" If you want to be truly competitive, you have to constantly think about what could go wrong and react to it -- and the reaction can't take three or four months. ... Being competitive means having a plan in place that we can use immediately." -- Kavya Gopal, Head of US Oncology, GSK #REpharmaUSA
Can pharma really call itself "agile" when it takes a year to make a TV ad and 12 years to develop a drug? GSK's Kavya Gopal asks. Yes! pharma's digital transformation during COVID-19 proves it. #REpharmaUSA
On tariffs and US manufacturing, Hilperdink says he hopes the conversation will consider operations holistically -- pharma companies may not do all their manufacturing in the US, but R&D and clinical trials are happening here and that's important as well. #REpharmaUSA
"Obesity right now I look at like Type 2 diabetes 25 years ago. We used to blame the patient for giving themselves Type 2 diabetes. … I think we all understand as a society now it's a complex, metabolic disease. Well why should obesity be any different?" -- Brian Hilberdink #REpharmaUSA
Now @boehringerglobal.bsky.social's Brian Hilberdink is on stage for an interview. #REpharmaUSA
He's talking about BI's upcoming entry into the obesity market. There are >100M potential patients but only about 3M getting treated with current drugs. So there's plenty of room in the market for more.
At #REpharmaUSA today in Philadelphia. Great crowd and energy. Hoping to post some updates and insights here throughout the next couple days.
